Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - methylphenidate hydrochloride, quantity: 54 mg - tablet, modified release - excipient ingredients: sodium chloride; phosphoric acid; stearic acid; iron oxide yellow; carnauba wax; povidone; polyethylene oxide; cellulose acetate; hypromellose; iron oxide black; succinic acid; butylated hydroxytoluene; poloxamer; iron oxide red; titanium dioxide; lactose monohydrate; triacetin; propylene glycol; isopropyl alcohol; purified water; macrogol 400 - concerta is indicated for the treatment of attention deficit hyperactivity disorder (adhd). treatment should be commenced by a specialist.,a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years.,need for comprehensive treatment programme concerta is indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. appropriate educational placement is essential and psychosocial intervention is often helpful. when remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician?s assessment of the chronicity and severity of the patient?s symptoms.,long term use the effectiveness of concerta for long-term use has not been systematically evaluated in controlled trials. therefore the physician who elects to use concerta for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - methylphenidate hydrochloride, quantity: 36 mg - tablet, modified release - excipient ingredients: stearic acid; poloxamer; polyethylene oxide; butylated hydroxytoluene; iron oxide black; iron oxide yellow; phosphoric acid; cellulose acetate; hypromellose; succinic acid; carnauba wax; sodium chloride; povidone; titanium dioxide; lactose monohydrate; triacetin; macrogol 400; propylene glycol; isopropyl alcohol; purified water - concerta is indicated for the treatment of attention deficit hyperactivity disorder (adhd). treatment should be commenced by a specialist.,a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years.,need for comprehensive treatment programme concerta is indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. appropriate educational placement is essential and psychosocial intervention is often helpful. when remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician?s assessment of the chronicity and severity of the patient?s symptoms.,long term use the effectiveness of concerta for long-term use has not been systematically evaluated in controlled trials. therefore the physician who elects to use concerta for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - methylphenidate hydrochloride, quantity: 18 mg - tablet, modified release - excipient ingredients: iron oxide yellow; sodium chloride; povidone; butylated hydroxytoluene; iron oxide black; stearic acid; polyethylene oxide; cellulose acetate; succinic acid; phosphoric acid; hypromellose; carnauba wax; poloxamer; macrogol 400; titanium dioxide; lactose monohydrate; triacetin; propylene glycol; isopropyl alcohol; purified water - concerta is indicated for the treatment of attention deficit hyperactivity disorder (adhd). treatment should be commenced by a specialist.,a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years.,need for comprehensive treatment programme concerta is indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. appropriate educational placement is essential and psychosocial intervention is often helpful. when remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician?s assessment of the chronicity and severity of the patient?s symptoms.,long term use the effectiveness of concerta for long-term use has not been systematically evaluated in controlled trials. therefore the physician who elects to use concerta for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Singapore - English - HSA (Health Sciences Authority)

dch auriga singapore - desogestrel (in blue tablet); desogestrel (in white tablet); ethinylestradiol (in blue tablet); ethinylestradiol (in white tablet) - tablet - 25 mcg - desogestrel (in blue tablet) 25 mcg; desogestrel (in white tablet) 125 mcg; ethinylestradiol (in blue tablet) 40 mcg; ethinylestradiol (in white tablet) 30 mcg

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sunzon international inc - aluminium phosphide - tablet (inc. pellet, bolus, suppository, capsule) - aluminium phosphide mineral-aluminium active 330.0 g/kg - insecticide - food product/commodity | grain handling machinery | shed,factory,warehouse or other building | stored barley seed | stored break - angoumois grain moth | bean weevil | cadelle | cigarette beetle | cockroach | coffee bean weevil | confused flour beetle | dried fruit beetle | flat grain beetle | granary weevil | hide or skin beetle | indian meal moth | lesser grain borer | maize weevil | mediterranean flour moth | merchant grain beetle | mottled grain moth | mouse - mus spp. | psocids or booklouse | raisin moth | rat | redlegged ham beetle | rice weevil | rust-red flour beetle | sawtoothed grain beetle | spider beetle | stored product mite | tobacco moth | tropical warehouse moth | warehouse beetle | dermestes ater | dermestes maculatus | grain borer | large cockroach | small cockroach | tobacco beetle

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin acetate, quantity: 0.2 mg (equivalent: desmopressin, qty 178 microgram) - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; povidone; potato starch - minirin tablets are indicated for the treatment of: cranial diabetes insipidus; primary nocturnal enuresis, in patients from 6 years of age with normal ability to concentrate urine, who are refractory to an enuresis alarm, or in whom an enuresis alarm is contraindicated or inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - clonazepam, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: iron oxide red; magnesium stearate; pregelatinised potato starch; purified talc; maize starch; iron oxide yellow; lactose monohydrate - tablets: most types epilepsy in infants and children, especially absences (petit mal), myoclonic seizures and tonic-clonic fits, whether due to primary generalised epilepsy, or to secondary generalisation of partial epilepsy. in adults all varieties of generalised epilepsy (including myoclonic, akinetic, tonic and tonic-clonic seizures), and in partial epilepsy (including psychomotor seizures).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - norethisterone, quantity: 350 microgram - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; lactose monohydrate; maize starch - indications as at 9 march 2003 : noriday is an oral contraceptive for women who will not, or cannot tolerate other oral contraceptives or intrauterine devices.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - quetiapine fumarate, quantity: 460 mg - tablet, modified release - excipient ingredients: hypromellose; microcrystalline cellulose; sodium citrate; magnesium stearate; titanium dioxide; macrogol 400; polysorbate 80 - quetiapine modified release tablets are indicated for:,bipolar disorder ? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,efficacy of quetiapine modified release tablets in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets.,schizophrenia treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy,major depressive disorder treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies,generalised anxiety disorder treatment of generalised anxiety disorder (gad)

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - quetiapine fumarate, quantity: 345 mg - tablet, modified release - excipient ingredients: hypromellose; microcrystalline cellulose; sodium citrate; magnesium stearate; titanium dioxide; macrogol 400; iron oxide yellow; iron oxide red; iron oxide black; polysorbate 80 - quetiapine modified release tablets are indicated for:,bipolar disorder ? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,efficacy of quetiapine modified release tablets in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets.,schizophrenia treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy,major depressive disorder treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies,generalised anxiety disorder treatment of generalised anxiety disorder (gad)